Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.52 |
| ▸ | PNP | P00491 | 3/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517600 | 1.00 | ADORA3 (0.56) | ADORA3STING1PNPHPRT1POLB | |
| SCHEMBL9386094 | 1.00 | ADORA3 (0.56) | ADORA3STING1PNPHPRT1POLB | |
| SCHEMBL12642438 | 1.00 | ADORA3 (0.56) | ADORA3STING1PNPHPRT1POLB | |
| SCHEMBL8913486 | 1.00 | ADORA3 (0.56) | ADORA3STING1PNPHPRT1POLB | |
| SCHEMBL8913491 | 1.00 | ADORA3 (0.56) | ADORA3STING1PNPHPRT1POLB | |
| SCHEMBL21942766 | 0.89 | ADORA3 (0.52) | ADORA3STING1PNPHPRT1TK1 | |
| SCHEMBL22381969 | 0.89 | ADORA3 (0.52) | ADORA3STING1PNPHPRT1TK1 | |
| SCHEMBL20324662 | 0.85 | POLB (0.56) | ADORA3PNPHPRT1POLB | |
| SCHEMBL8912238 | 0.83 | ALDH1A1 (0.54) | ADORA3STING1HPRT1 | |
| SCHEMBL8913594 | 0.83 | ALDH1A1 (0.54) | ADORA3STING1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0491793-A4 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | — | 1993-03-03 | — | — | EP | claimed |
| EP-0491793-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-01 | — | — | EP | claimed |
| WO-1991004033-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-04-04 | — | — | WO | claimed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3004130-B1 | 1',4'-THIO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-1994001117-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| EP-0491793-A4 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0491793-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1991004033-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA3 110/4885STING1 1/4885PNP 305/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA3 110/4885STING1 1/4885PNP 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.